UNITED THERAPEUTICS Corp — Form 8-K
Filed October 22, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
On October 22, 2026, United Therapeutics' Board authorized a new $2 billion share repurchase program, exercisable through October 21, 2027. Repurchases may occur via accelerated share repurchase (ASR), open market transactions, or private negotiations, at management's discretion with no minimum purchase requirement. The company has an ongoing ASR transaction from September 2026 that will terminate in Q4 2026 and will not reduce the new authorization.
Why this rating
At $11.2B market value, $2B represents ~18% of equity—material but not transformational. Signals confidence; typical capital allocation tool. No immediate operational impact.
See more from October 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.